1. Picarbutrazox Effectiveness Added to a Seed Treatment Mixture for Management of Oomycetes that Impact Soybean in Ohio.
- Author
-
Dorrance AE, Vargas A, Navarro-Acevedo K, Wijertatne S, Myers J, and Paredes JA
- Subjects
- Ohio, Rhizosphere, Glycine max microbiology, Fungicides, Industrial pharmacology, Plant Diseases prevention & control, Plant Diseases microbiology, Plant Diseases parasitology, Seeds microbiology, Oomycetes drug effects
- Abstract
None of the current oomycota fungicides are effective towards all species of Phytophthora , Phytopythium , Globisporangium , and Pythium that affect soybean seed and seedlings in Ohio. Picarbutrazox is a new oomyceticide with a novel mode of action towards oomycete pathogens. Our objectives were to evaluate picarbutrazox to determine (i) baseline sensitivity (EC
50 ) to 189 isolates of 29 species, (ii) the efficacy with a base seed treatment with three cultivars with different levels of resistance in 14 field environments; and (iii) if the rhizosphere microbiome was affected by the addition of the seed treatment on a moderately susceptible cultivar. The mycelial growth of all isolates was inhibited beginning at 0.001 μg, and the EC50 ranged from 0.0013 to 0.0483 μg of active ingredient (a.i.)/ml. The effect of seed treatment was significantly different for plant population and yield in eight of 14 and six of 12 environments, respectively. The addition of picarbutrazox at 1 and 2.5 g of a.i./100 kg seed to the base seed treatment compared to the base alone was associated with higher plant populations and yield in three and one environments, respectively. There was limited impact of the seed treatment mefenoxam 7.5 g of a.i. plus picarbutrazox 1 g of a.i./100 kg seed on the oomycetes detected in the rhizosphere of soybean seedlings collected at the V1 growth stage. Picarbutrazox has efficacy towards a wider range of oomycetes that cause disease on soybean, and this will be another oomyceticide tool to combat early season damping-off in areas where environmental conditions highly favor disease development., Competing Interests: The author(s) declare no conflict of interest.- Published
- 2024
- Full Text
- View/download PDF